Skip to main content
SpringerLink
Log in

Prevention of Osteoporosis

Current Recommendations

  • Review Articles
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Osteoporosis and its treatment have attracted much attention in recent years, especially since the widespread recognition of its association with the menopause.

The resulting fractures are a cause of considerable morbidity and mortality in the elderly, and current costs of treating these patients has been estimated to be in excess of £500 million per annum in the UK. As the causes of osteoporosis are now recognised the condition may be largely preventable, especially in women, and significant savings in health expenditure could be made if preventive methods are applied to those most at risk.

The most well researched preventive treatment for osteoporosis is hormone replacement therapy (HRT) which offers additional benefits to those who choose it. Alternative methods currently under investigation for those who cannot or will not use HRT include those agents which inhibit the resorption of bone and those that stimulate the production of new bone.

Treatment of established disease, i.e. attempts at increasing bone density in those with significant loss, is more difficult and methods so far investigated are not without risks and adverse effects. Furthermore, whether an increase in bone mineral density results in a reduced rate of fracture incidence has yet to be confirmed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abadallah H, Hart DM, Lindsay R. Differential bone loss and effects of long term estrogen therapy according to time of introduction of therapy after oophorectomy. In Christiansen et al. (Eds) Osteoporosis: Proceedings of the Copenhagen Symposium on Osteoporosis, pp. 621–623, Glosstrup, Glosstrup Hospital, 1984

  • Aitken JM, Armstrong E, Anderson JB. Osteoporosis after oophorectomy in the mature female rat and effect of oestrogen and/ or progestogen replacement therapy in its prevention. Journal of Endocrinology 55: 79–87, 1972

    Article  PubMed  CAS  Google Scholar 

  • Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, et al. Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine 84: 410, 1988

    Article  Google Scholar 

  • Bush TL, Barratt-Connor B, Cowan LD, Criqui MH, Wallace RB. Cardiovascular mortality and non-contraceptive use of oestrogen in women. Results from the Lipid Research Clinics Programme follow up study. Circulation 75: 1102–1109, 1987

    Article  PubMed  CAS  Google Scholar 

  • Chesnut CH. Treatment of postmenopausal osteoporosis; some current concepts. Scottish Medical Journal 26: 72–80, 1981

    PubMed  Google Scholar 

  • Chow R, Harrison JE, Notarius C. Effect of two randomised exercise programmes on bone mass of healthy women. British Medical Journal 295: 40–44, 1987

    Article  Google Scholar 

  • Christiansen C, Christiansen GS, McNair P, Hagen C, Stocklund KE, et al. Prevention of early postmenopausal bone loss: a controlled study in 350 normal females. European Journal of Clinical Investigation 10: 273–279, 1980

    Article  PubMed  CAS  Google Scholar 

  • Christiansen C, Christiansen MS, Larsen NE, Transbol I. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. Journal of Clinical Endocrinology and Metabolism 55: 1124–1130, 1982

    Article  PubMed  CAS  Google Scholar 

  • Christiansen C, Christiansen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1: 459–461, 1981

    Article  PubMed  CAS  Google Scholar 

  • Civitelli R, Agnus Dei D, Nardi P, Zachei F, Aveoli LV, et al. Effects of one year treatment with oestrogens on bone mass, intestinal calcium absorption and 1, 25-hydroxyvitamin D1-alpha hydroxylase reserve in postmenopausal osteoporosis. Calcified Tissue International 42: 77–86, 1988

    Article  PubMed  CAS  Google Scholar 

  • Coleston KW, King RJB, Hayward J, Fraser DI, Horton MA, et al. Oestrogen receptors and human bone cells: immunocyto-chemical studies. Journal of Bone and Mineral Research 4: 625–631, 1989

    Article  Google Scholar 

  • Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, et al. Comparison of transdermal and oral estrogen/progestin replacement therapy: effects on serum lipids and lipoproteins. American Journal of Obstetrics and Gynecology 166: 950–955, 1992

    PubMed  CAS  Google Scholar 

  • Dempster DW, Shane E, Herbert E, Lindsay R. Journal of Bone and Mineral Research 1: 19, 1986

    Google Scholar 

  • Ettinger B, Gennant HK, Cann CE. Postmenopausal bone loss is prevented by low dose oestrogen with calcium. Annals of Internal Medicine 106: 40–45, 1987

    PubMed  CAS  Google Scholar 

  • Ettinger B, Gennant HK, Cann CE. Long term oestrogen therapy prevents bone loss and fracture. Annals of Internal Medicine 102: 319–324, 1985

    PubMed  CAS  Google Scholar 

  • Feyen JHM, Raisz LG. Prostaglandin production by calvariae from sham operated and oophorectomized rats: effects of 17B-oes-tradiol in vivo. Endocrinology 121: 819–821, 1987

    Article  PubMed  CAS  Google Scholar 

  • Fleisch H. Bisphosphonates: history and mechanism of action. Metabolic Bone Disease and Related Research 3: 279–287, 1981

    Article  CAS  Google Scholar 

  • Fleisch H. Experimental basis for the use of bisphosphonates in Paget’s disease of bone. Clinical Orthopaedics and Related Research 217: 72–78, 1987

    PubMed  Google Scholar 

  • Gallagher JC, Goldger D, Moy A. Total body calcium in normal women: effect of age and menopausal state. Bone Mineral Research 2: 491–496, 1987

    Article  CAS  Google Scholar 

  • Gennant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computerised tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Annals of Internal Medicine 97: 699–705, 1982

    Google Scholar 

  • Godsland IF, Shennan NM, Wynn V. Insulin action and dynamics modelled in patients taking the anabolic extort methandienone (Dianabol). Clinical Science 71: 665–673, 1986

    PubMed  CAS  Google Scholar 

  • Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, et al. Long term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33: 295–303, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hassagher C, Podenphant J, Riis BJ, Johannsen JS, Jensen J, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 38: 238–242, 1989

    Article  Google Scholar 

  • Haussler MR, Donaldson CA, Allegreto EA, et al. New actions of 1, 25 dihydroxy vitamin D3: possible clues to the pathogenesis of postmenopausal osteoporosis. In Christiansen et al. (Eds) Osteoporosis, pp. 725–736, Aalborg, Stiftsbogtrykkeri, 1984

    Google Scholar 

  • Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clinical Pharmacology and Therapeutics 20: 593–604, 1976

    PubMed  CAS  Google Scholar 

  • Hedlund LR, Gallagher JC. Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. Journal of Bone and Mineral Research 4: 223–225, 1989

    Article  PubMed  CAS  Google Scholar 

  • Henderson BE, Ross RK, Paganini-Hill A. Oestrogen use and cardiovascular disease. Journal of Reproductive Medicine 30 (Suppl.): 814–820, 1985

    PubMed  CAS  Google Scholar 

  • Hillyard CJ, Stevenson JC, Maclntyre I. Relative deficiency of plasma calcitonin in normal women. Lancet 1: 961–962, 1978

    Article  PubMed  CAS  Google Scholar 

  • Horsman A, Gallagher JC, Simple M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. British Medical Journal 2: 789–792, 1977

    Article  PubMed  CAS  Google Scholar 

  • Hutchinson TA, Polanski SM, Feinstein AR. Postmenopausal oestrogens protect against fractures of hip and distal radius. Lancet 2: 705–709, 1979

    Article  PubMed  CAS  Google Scholar 

  • Johannsen JS, Hassagher C, Podenphant J, Riis BJ, Hartwell D, et al. Treatment of postmenopausal osteoporosis. Is the anabolic steroid nandrolone decanoate a candidate? Bone and Mineral 6: 77–86, 1989

    Article  Google Scholar 

  • Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. New England Journal of Medicine 327: 82–87, 1992

    Article  PubMed  Google Scholar 

  • Kanis JA, Gray RE. Long term follow up observations on treat-ment in Paget’s disease of bone. Clinical Orthopaedics and Related Research 217: 119–125, 1987

    Google Scholar 

  • Kanis JA, Passmore R. Calcium supplementation of the diet, I & II. British Medical Journal 293: 137–140 & 205-208, 1989

    Article  Google Scholar 

  • Krolner B, Neilsen SP. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross sectional and longitudinal studies. Clinical Science 62: 329–336, 1982

    PubMed  CAS  Google Scholar 

  • Laragh JH, Seeley JE, Leddinghum JG, Newton MA. Oral contraceptives; renin aldosterone and high blood pressure. Journal of the American Medical Association 201: 918–922, 1967

    Article  PubMed  CAS  Google Scholar 

  • Lindsay R, Hart DM, Cark DM. The minimum effective dose of oestrogen for prevention of postmenopausal bone loss. Obstetrics and Gynecology 63: 759–763, 1984

    PubMed  CAS  Google Scholar 

  • Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet 1: 1325–1327, 1978

    Article  PubMed  CAS  Google Scholar 

  • Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, et al. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clinical Science and Molecular Medicine 54: 193–195, 1978

    PubMed  CAS  Google Scholar 

  • Lindsay R, Tohme JF. Oestrogen treatments of patients with established postmenopausal osteoporosis. Obstetrics and Gynecology 76: 290–295, 1990

    PubMed  CAS  Google Scholar 

  • Lindsay RL, Hart DM, Aitken JM, MacDonald EB, Anderson JB, et al. Long term prevention of osteoporosis by oestrogen. Lancet 1: 1038–1041, 1976

    Article  PubMed  CAS  Google Scholar 

  • Lindsay RL, Hart DM, Forest C, Baird C. Prevention of osteoporosis in oophorectomized women. Lancet 2: 1151–1154, 1980

    Article  PubMed  CAS  Google Scholar 

  • MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1: 900–902, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2: 361–365, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mandell FP, Davidson BJ, Erlich Y, Judd HL, Meldrum DR. Effects of progestin on bone metabolism in postmenopausal women. Journal of Reproductive Medicine 27: 511–514, 1982

    Google Scholar 

  • Mashchak CA, Lobo RA, Dozono-Takana R, Eggena P, Nakamura RM, et al. Comparison of pharmacodynamic properties of various estrogen formulations. American Journal of Obstetrics and Gynecology 144: 511–518, 1982

    PubMed  CAS  Google Scholar 

  • Nachtigall LE, Nachtigall RH, Nachtigall RD. Oestrogen replacement therapy: a ten year prospective study in the relationship to osteoporosis. Obstetrics and Gynecology 53: 277–281, 1979

    PubMed  CAS  Google Scholar 

  • Nordin BEC, Heaney RP. Calcium supplementation of the diet: justified by present evidence. British Medical Journal 300: 1056–1060, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Annals of Internal Medicine 110: 267–274, 1989

    PubMed  CAS  Google Scholar 

  • Overgaard K, Riis BJ, Christiansen C. Podenphant J, Johennsen JS. Nasal calcitonin for treatment of established osteoporosis. Clinical Endocrinology 30: 435–442, 1989

    Article  PubMed  CAS  Google Scholar 

  • Quigley MET, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. American Journal of Obstetrics and Gynecology 156: 1516–1523, 1987

    PubMed  CAS  Google Scholar 

  • Recker RR, Saville PD, Heaney RP. Effects of oestrogen and calcium carbonate on bone loss. Annals of Internal Medicine 87: 649–655, 1977

    PubMed  CAS  Google Scholar 

  • Reginster JY, Deroisy R, Albert A, Denis D, Lecart MP, et al. Relationship between whole plasma calcitonin levels, calcitonin secretory capacity and plasma levels of estrone in healthy women and postmenopausal osteoporosis. Journal of Clinical Investigation 83: 1073–1077, 1989

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P, et al. One year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2: 1481–1483, 1987

    Article  PubMed  CAS  Google Scholar 

  • Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, et al. Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine 322: 802–809, 1990

    Article  PubMed  CAS  Google Scholar 

  • Royal College of General Practitioners, oral contraceptives study. Oral contraceptives, venous thrombosis and varicose veins. Journal of the Royal College of General Practitioners 28: 393–399, 1977

    Google Scholar 

  • Schaadt O, Bohr H. Different trends of age-related diminution of bone mineral content in the lumbar spine, femoral neck, and femoral shaft in women. Calcified Tissue International 42: 71–76, 1988

    Article  PubMed  CAS  Google Scholar 

  • Smith DM, Nance WE, Kang KW, Christian JC, Johnston CC. Genetic factors determining bone loss. Journal of Clinical Investigation 52: 2800–2808, 1973

    Article  PubMed  CAS  Google Scholar 

  • Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. New England Journal of Medicine 319: 1313–1317, 1988

    Article  PubMed  CAS  Google Scholar 

  • Stevenson JC. Postmenopausal bone loss and osteoporosis; epidemiological aspects. In Zichella et al. (Eds) The climacteric and beyond, pp. 127–129, Parthenon Publishing group, Carn-forth, England, 1988

    Google Scholar 

  • Stevenson JC, Lees B, Banks LM, Whitehead MI. Assessment of therapeutic options for prevention of bone loss. In Christiansen et al. (Eds). Osteoporosis (1987), pp. 489–493, Viborg, Nor-haven, Bogtrykken A/S, Osteopress, 1987

    Google Scholar 

  • Stevenson JC, Lees B, Devenport M, Cust MP, Gangar KF. Determinants of bone density in normal women: risk factors for future osteoporosis? British Medical Journal 298: 924, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stevenson JC, Abeyasekera G, Hillyard CJ, Phang KG, Maclntyre I, et al. Calcitonin and the calcium regulating hormones in postmenopausal women: effects of oestrogens. Lancet 1: 693–695, 1982

    Google Scholar 

  • Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 335: 265–269, 1990

    Article  Google Scholar 

  • Storm T, Thamsborg G, Gennant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New England Journal of Medicine 322: 1265–1271, 1990

    Article  PubMed  CAS  Google Scholar 

  • Watts NB, Harris ST, Gennant HK, Wasnich RD, Miller PD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New England Journal of Medicine 323: 73–79, 1990

    Article  PubMed  CAS  Google Scholar 

  • Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risks of fractures of the hip and lower forearm with postmenopausal use of oestrogen. New England Journal of Medicine 303: 1195–1198, 1980

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wynn Institute for Metabolic Research, 21 Wellington Rd, London, NW8 9SQ, England

    Michael C. Ellerington & John C. Stevenson

Authors
  1. Michael C. Ellerington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John C. Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellerington, M.C., Stevenson, J.C. Prevention of Osteoporosis. Drug & Aging 2, 508–517 (1992). https://doi.org/10.2165/00002512-199202060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199202060-00006

Keywords

Search

Navigation